Life Sciences X. L.P. Frazier Acquires 625,000 Shares of MBX Biosciences, Inc. (NYSE:MBX) Stock

MBX Biosciences, Inc. (NYSE:MBX) major shareholder Life Sciences X. L.P. Frazier bought 625,000 shares of the business’s stock in a transaction that occurred on Monday, September 16th. The stock was acquired at an average cost of $16.00 per share, for a total transaction of $10,000,000.00. Following the completion of the purchase, the insider now directly owns 4,552,774 shares of the company’s stock, valued at $72,844,384. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Major shareholders that own more than 10% of a company’s shares are required to disclose their transactions with the SEC.

MBX Biosciences Trading Down 2.3 %

Shares of MBX opened at $21.00 on Thursday. MBX Biosciences, Inc. has a one year low of $20.51 and a one year high of $26.08.

MBX Biosciences Company Profile

MBX Biosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is MBX 2109, a parathyroid hormone peptide prodrug, which is in Phase 2 clinical trial designed as a potential long-acting hormone replacement therapy for the treatment of chronic hypoparathyroidism.